Monoclonal Antibody Therapy for Hematologic Malignancies PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Monoclonal Antibody Therapy for Hematologic Malignancies PDF full book. Access full book title Monoclonal Antibody Therapy for Hematologic Malignancies by John C. Byrd. Download full books in PDF and EPUB format.
Author: John C. Byrd
Publisher:
ISBN:
Category :
Languages : en
Pages : 140
Get Book Here
Book Description
Author: John C. Byrd
Publisher:
ISBN:
Category :
Languages : en
Pages : 140
Get Book Here
Book Description
Author:
Publisher:
ISBN:
Category : Monoclonal antibodies
Languages : en
Pages : 46
Get Book Here
Book Description
Author: Steven T. Rosen
Publisher: Springer Science & Business Media
ISBN: 1461530768
Category : Medical
Languages : en
Pages : 293
Get Book Here
Book Description
The hybridoma technique for producing monoclonal antibodies, developed by Drs. Kohler and Millstein in 1975, revolutionized the field of tumor immunology. It is now clear that there are antigens associated with or restricted to human neoplasms that have biologic significance. Monoclonal antibodies have already been demonstrated to have great immunodiagnostic value and it is anticipated that they will become a component of our therapeutic armamentarium. Most investigators in the field, however, feel that the true potential of monoclonal antibodies in cancer therapy remains to be determined. Clearly the most encouraging results have been witnessed in the treatment of hematologic malignancies. This volume of CANCER TREATMENT AND RESEARCH explores the current state of the art of immunoconjugate therapy of hematologic malignancies. Immunoconjugate Therapy of Hematologic Malignancies provides an update of a rapidly advancing field. The preliminary experience of a number of investigators suggests a role for targeted therapy in the treatment of hematologic malignancies. At the present time, immunoconjugates have, in most instances, been reserved for patients with advanced refractory disease. However, it is anticipated in the future that these reagents will be utilized as a complement to traditional therapy or as post-remission consolidation in patients with minimal residual disease. The obstacles have been defined; solutions will require further research and creative imagination.
Author:
Publisher:
ISBN:
Category : Hematological oncology
Languages : en
Pages : 46
Get Book Here
Book Description
Author: Bruce D. Cheson
Publisher:
ISBN:
Category : Biology
Languages : en
Pages : 318
Get Book Here
Book Description
Author: American Society of Hematology
Publisher:
ISBN:
Category :
Languages : en
Pages :
Get Book Here
Book Description
Author: American Society of Hematology
Publisher:
ISBN:
Category :
Languages : en
Pages :
Get Book Here
Book Description
Author: Brian A. Baldo
Publisher: Springer
ISBN: 3319304720
Category : Medical
Languages : en
Pages : 623
Get Book Here
Book Description
This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the world's 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world's 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of Biologics Therapy examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern biologics therapy is increasingly being demanded of all those connected with their development, handling, prescribing, administration and subsequent patient management. In addition to being of great value to clinicians in all branches of medicine, and to nurses, pharmacists and researchers, this book will prove invaluable for students taking undergraduate and graduate courses in the above disciplines and in the biomedical sciences.
Author: Jonathan W. Friedberg
Publisher:
ISBN:
Category : Hematology
Languages : en
Pages : 132
Get Book Here
Book Description
Author: Kenneth A. Foon
Publisher: Springer Science & Business Media
ISBN: 1461326273
Category : Medical
Languages : en
Pages : 171
Get Book Here
Book Description
KENNETH A. FOON and ALTON C. MORGAN, JR. Passive immunotherapy using heteroantisera for the treatment of cancer in animals and humans has been studied for over 50 years. Attempts have been made to treat animal tumors with sera from immunized syngeneic, allogeneic, or xenogeneic animals. A number of studies of passive immunotherapy using heterologous antisera in humans have also been performed. These studies have generally been attempted in patients with large tumor burdens, and as would be expected, results have been transient at best. A wide variety of solid tumors as well as leukemias and lym phomas have been treated with antisera raised in sheep, horses, rabbits, and goats. Problems such as anaphylaxis, serum sick ness, and severe cytopenias have been encountered with these antisera. There are a number of potential mechanisms by which unconju gated antibodies might be cytotoxic to tumor cells. Antibodies bound to the cell surface membrane of tumor cells may lead to cell lysis by complement-dependent or antibody-dependent cellu lar cytotoxicity. Circulating tumor cells bound by antibody may be more susceptible to phagocytosis by the reticuloendothelial system. Antibody bound to the cell surface membrane of tumor cells may enhance immunogenicity of the tumor cell leading to activation of the host's immune system.
